

Biotechnology Valuation & Investing: Biotech Valuation & Investing

By Dr. Dimitrios Iliopoulos



Biotechnology Valuation & Investing: Biotech Valuation & Investing By Dr. **Dimitrios Iliopoulos**

Janet Yellen, the Fed Chair, recently said that the valuations of small-cap biotechnology companies are substantially stretched. Biotechnology is a relatively new science and during the last few years there is an increasing number of new biotech start-up companies and also M&A activity between biotech startups and large biotechnology and pharmaceutical companies. Few years ago, we observed one of the largest acquisitions in the biotech sector, by having Amgen buying Onyx Pharmaceuticals for more than \$9 billion dollars. More recently, Moderna Therapeutics, a biotech company developing mRNA therapeutics, broke the record of VC funding, raising \$450 million dollars in a single round of funding, without having a product in the market. All these recent events raise an important question: what are the valuation financial models used in the biotechnology industry? How could we value a company having negative cash flows for several years, without any product in the market? How do we value a company developing a CRISPR therapeutics currently in the preclinical level? Is there any difference on valuating a phase II drug against arthritis vs a phase II anti-cancer drug? This book is aiming to answer these essential questions by describing the key aspects of the drug discovery process, including novel financial models used for valuation of biotech companies. Furthermore, we have created new biotech valuation cases providing to the reader a practical guide for valuation of any biotech product or company.



Read Online Biotechnology Valuation & Investing: Biotech Val ...pdf

Biotechnology Valuation & Investing: Biotech Valuation & Investing

By Dr. Dimitrios Iliopoulos

Biotechnology Valuation & Investing: Biotech Valuation & Investing By Dr. Dimitrios Iliopoulos

Janet Yellen, the Fed Chair, recently said that the valuations of small-cap biotechnology companies are substantially stretched. Biotechnology is a relatively new science and during the last few years there is an increasing number of new biotech start-up companies and also M&A activity between biotech start-ups and large biotechnology and pharmaceutical companies. Few years ago, we observed one of the largest acquisitions in the biotech sector, by having Amgen buying Onyx Pharmaceuticals for more than \$9 billion dollars. More recently, Moderna Therapeutics, a biotech company developing mRNA therapeutics, broke the record of VC funding, raising \$450 million dollars in a single round of funding, without having a product in the market. All these recent events raise an important question: what are the valuation financial models used in the biotechnology industry? How could we value a company having negative cash flows for several years, without any product in the market? How do we value a company developing a CRISPR therapeutics currently in the preclinical level? Is there any difference on valuating a phase II drug against arthritis vs a phase II anti-cancer drug? This book is aiming to answer these essential questions by describing the key aspects of the drug discovery process, including novel financial models used for valuation of biotech companies. Furthermore, we have created new biotech valuation cases providing to the reader a practical guide for valuation of any biotech product or company.

Biotechnology Valuation & Investing: Biotech Valuation & Investing By Dr. Dimitrios Iliopoulos Bibliography

Rank: #1555023 in Books
Brand: Ingramcontent
Published on: 2016-11-01
Original language: English

• Dimensions: 11.00" h x .51" w x 8.50" l,

• Binding: Paperback

• 214 pages

<u>Download</u> Biotechnology Valuation & Investing: Biotech Valua ...pdf

Read Online Biotechnology Valuation & Investing: Biotech Val ...pdf

Download and Read Free Online Biotechnology Valuation & Investing: Biotech Valuation & Investing By Dr. Dimitrios Iliopoulos

Editorial Review

About the Author

Dimitrios Iliopoulos is an Associate Professor of Medicine, in the Vatche and Tamar Manoukian Division of Digestive Diseases at UCLA David Geffen School of Medicine and the Founding Director of the UCLA Center for Systems Biomedicine, a high technology center combining novel technologies aiming to expedite the drug discovery process for different human diseases. Furthermore, he is founder of Algorithm Therapeutics Inc, a biotech company developing epigenetic drugs for patients with inflammatory diseases. He started his academic career as an Assistant Professor at Dana-Farber Cancer Institute and Harvard Medical School. He has received an Executive MBA degree from UCLA Anderson School of Management, having a specialization in financial valuation and modeling of the biotechnology and healthcare sectors. More recently, Dr. Iliopoulos received a certificate from Stanford Graduate School of Business on Mergers & Acquisitions. Dimitrios is a consultant to several pharma and biotech companies and has collaborated with venture capital firms and major investment banks in projects related to biotech company financial valuation. Jason Hsu is the CEO and Chairman of Rayliant Global Advisors, an investment management firm focused on smart beta strategies tailored to the Asian markets as well as Chinese equity strategies targeted at foreign institutional investors. Jason graduated with a BS in physics from the California Institute of Technology, an MS in Finance from Stanford University and a PhD in Finance from UCLA, where he conducted research on the equity premium and portfolio allocations. Currently, he is a Member of the Board of Directors at the Anderson School of Management at UCLA, as well as an Adjunct Professor of Finance. He is also a cofounder of Research Affiliates, currently serving as a Vice Chairman and Advisor. Building on his pioneering work on the RAFI Fundamental Index approach to investing, he has published numerous articles on the topic, notably including "A survey of alternative equity index strategies", which won a 2011 Graham and Dodd Schroll and the Readers' Choice Award from the CFA Institute. In 2013, he received the William F. Sharpe Award for Best New Index Research. Dr. Hsu has authored more than 40 peer-reviewed articles and he is an Associate Editor in the Journal of Investment Management.

Users Review

From reader reviews:

Joel Faulkner:

Book will be written, printed, or descriptive for everything. You can understand everything you want by a e-book. Book has a different type. To be sure that book is important issue to bring us around the world. Close to that you can your reading talent was fluently. A book Biotechnology Valuation & Investing: Biotech Valuation & Investing will make you to end up being smarter. You can feel a lot more confidence if you can know about almost everything. But some of you think that will open or reading some sort of book make you bored. It is far from make you fun. Why they could be thought like that? Have you looking for best book or suited book with you?

Lenora Dryer:

What do you with regards to book? It is not important along with you? Or just adding material when you need something to explain what you problem? How about your extra time? Or are you busy man or woman?

If you don't have spare time to complete others business, it is make you feel bored faster. And you have time? What did you do? Every individual has many questions above. They have to answer that question simply because just their can do this. It said that about book. Book is familiar on every person. Yes, it is proper. Because start from on guardería until university need this Biotechnology Valuation & Investing: Biotech Valuation & Investing to read.

Thomas Towne:

Playing with family in a park, coming to see the coastal world or hanging out with close friends is thing that usually you have done when you have spare time, in that case why you don't try matter that really opposite from that. One particular activity that make you not sensation tired but still relaxing, trilling like on roller coaster you have been ride on and with addition associated with. Even you love Biotechnology Valuation & Investing: Biotech Valuation & Investing, you can enjoy both. It is great combination right, you still would like to miss it? What kind of hangout type is it? Oh occur its mind hangout folks. What? Still don't have it, oh come on its known as reading friends.

Eugene Howard:

This Biotechnology Valuation & Investing: Biotech Valuation & Investing is fresh way for you who has interest to look for some information since it relief your hunger of information. Getting deeper you into it getting knowledge more you know or perhaps you who still having bit of digest in reading this Biotechnology Valuation & Investing: Biotech Valuation & Investing can be the light food for you personally because the information inside this specific book is easy to get by simply anyone. These books produce itself in the form which can be reachable by anyone, yep I mean in the e-book type. People who think that in guide form make them feel sleepy even dizzy this book is the answer. So there is not any in reading a publication especially this one. You can find what you are looking for. It should be here for anyone. So , don't miss the idea! Just read this e-book style for your better life along with knowledge.

Download and Read Online Biotechnology Valuation & Investing: Biotech Valuation & Investing By Dr. Dimitrios Iliopoulos #HNULXIQS1RT

Read Biotechnology Valuation & Investing: Biotech Valuation & Investing By Dr. Dimitrios Iliopoulos for online ebook

Biotechnology Valuation & Investing: Biotech Valuation & Investing By Dr. Dimitrios Iliopoulos Free PDF d0wnl0ad, audio books, books to read, good books to read, cheap books, good books, online books, books online, book reviews epub, read books online, books to read online, online library, greatbooks to read, PDF best books to read, top books to read Biotechnology Valuation & Investing: Biotech Valuation & Investing By Dr. Dimitrios Iliopoulos books to read online.

Online Biotechnology Valuation & Investing: Biotech Valuation & Investing By Dr. Dimitrios Iliopoulos ebook PDF download

Biotechnology Valuation & Investing: Biotech Valuation & Investing By Dr. Dimitrios Iliopoulos Doc

Biotechnology Valuation & Investing: Biotech Valuation & Investing By Dr. Dimitrios Iliopoulos Mobipocket

Biotechnology Valuation & Investing: Biotech Valuation & Investing By Dr. Dimitrios Iliopoulos EPub

HNULXIQS1RT: Biotechnology Valuation & Investing: Biotech Valuation & Investing By Dr. Dimitrios Iliopoulos